ArticleScientific reports2025
Cost-effective method for semi-quantitative analysis of soluble endoglin in biological samples after anti-endoglin monoclonal antibody treatment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-endoglin monoclonal antibody TRC105 prevents the increase of liver inflammatory biomarkers in a mouse model of cholestasis.Cellular and molecular life sciences : CMLS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Soluble endoglin (sENG) is an important biomarker of several cardiometabolic and vascular disorders. The accurate measurement of biomarkers that are simultaneously targeted by therapeutic monoclonal antibodies (mAbs) in preclinical models is a significant challenge. Traditional enzyme-linked immunosorbent assays (ELISAs) often fail due to epitope blocking, while advanced techniques like mass spectrometry are more expensive and require specialized expertise. To address these limitations, we developed a cost-effective, specific Western blot-based method for evaluating sENG in mouse plasma in a metabolic dysfunction-associated steatohepatitis (MASH) rescue model. Thus, from a methodological perspective, we significantly modified and extended the sENG detection method introduced in our previous work, focusing on developing a cost-effective approach for semi-quantitative analysis. For these purposes, we used a mouse MASH model treated with the anti-endoglin (ENG) mAb M1043. Plasma samples were concentrated, and proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and probed with an anti-ENG antibody. We verified the method using human hepatic sinusoidal endothelial cells (HHSECs) culture media treated with the therapeutic human anti-ENG monoclonal antibody, TRC105. This Western blot-based approach avoids interference from therapeutic mAbs, delivering reliable and reproducible results. This method overcomes the limitations of ELISAs and mass spectrometer, providing a practical solution for semi-quantitative analysis of biomarkers in both preclinical and clinical research. Its versatility makes it applicable to various soluble protein biomarkers across diseases. As therapeutic mAbs become more widely used, this simple, cost-effective method facilitates mechanistic insights and accelerates targeted therapy development in research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.